Annual EBITDA
-$125.85 M
-$41.10 M-48.49%
December 31, 2023
Summary
- As of February 8, 2025, RAPT annual EBITDA is -$125.85 million, with the most recent change of -$41.10 million (-48.49%) on December 31, 2023.
- During the last 3 years, RAPT annual EBITDA has fallen by -$73.75 million (-141.59%).
- RAPT annual EBITDA is now -350.30% below its all-time high of -$27.95 million, reached on December 31, 2017.
Performance
RAPT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$19.49 M
+$9.53 M+32.85%
September 30, 2024
Summary
- As of February 8, 2025, RAPT quarterly EBITDA is -$19.49 million, with the most recent change of +$9.53 million (+32.85%) on September 30, 2024.
- Over the past year, RAPT quarterly EBITDA has increased by +$14.10 million (+41.98%).
- RAPT quarterly EBITDA is now -142.24% below its all-time high of -$8.05 million, reached on June 30, 2018.
Performance
RAPT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$113.61 M
+$14.10 M+11.04%
September 30, 2024
Summary
- As of February 8, 2025, RAPT TTM EBITDA is -$113.61 million, with the most recent change of +$14.10 million (+11.04%) on September 30, 2024.
- Over the past year, RAPT TTM EBITDA has increased by +$3.52 million (+3.00%).
- RAPT TTM EBITDA is now -1311.18% below its all-time high of -$8.05 million, reached on March 31, 2018.
Performance
RAPT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RAPT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -48.5% | +42.0% | +3.0% |
| 3 y3 years | -141.6% | -6.5% | -79.7% |
| 5 y5 years | -252.4% | -95.4% | -168.6% |
RAPT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -84.5% | at low | -9.5% | +42.0% | -66.6% | +11.0% |
| 5 y | 5-year | -197.5% | at low | -60.9% | +42.0% | -168.6% | +11.0% |
| alltime | all time | -350.3% | at low | -142.2% | +42.0% | -1311.2% | +11.0% |
RAPT Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$19.49 M(-32.8%) | -$113.61 M(-11.0%) |
| Jun 2024 | - | -$29.02 M(-9.9%) | -$127.72 M(+0.7%) |
| Mar 2024 | - | -$32.20 M(-2.1%) | -$126.79 M(+0.7%) |
| Dec 2023 | -$125.85 M(+48.5%) | -$32.89 M(-2.1%) | -$125.85 M(+7.4%) |
| Sep 2023 | - | -$33.59 M(+19.6%) | -$117.13 M(+11.6%) |
| Jun 2023 | - | -$28.09 M(-10.1%) | -$104.95 M(+9.9%) |
| Mar 2023 | - | -$31.26 M(+29.3%) | -$95.50 M(+12.7%) |
| Dec 2022 | -$84.75 M(+24.2%) | -$24.18 M(+12.9%) | -$84.75 M(+8.1%) |
| Sep 2022 | - | -$21.42 M(+14.9%) | -$78.37 M(+4.1%) |
| Jun 2022 | - | -$18.64 M(-9.2%) | -$75.26 M(+3.9%) |
| Mar 2022 | - | -$20.52 M(+15.2%) | -$72.45 M(+6.2%) |
| Dec 2021 | -$68.21 M | -$17.80 M(-2.7%) | -$68.21 M(+7.9%) |
| Sep 2021 | - | -$18.30 M(+15.7%) | -$63.23 M(+6.7%) |
| Jun 2021 | - | -$15.82 M(-2.8%) | -$59.24 M(+6.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$16.28 M(+27.0%) | -$55.53 M(+6.6%) |
| Dec 2020 | -$52.09 M(+23.1%) | -$12.82 M(-10.5%) | -$52.09 M(+0.6%) |
| Sep 2020 | - | -$14.32 M(+18.2%) | -$51.77 M(+9.2%) |
| Jun 2020 | - | -$12.12 M(-5.6%) | -$47.42 M(+3.3%) |
| Mar 2020 | - | -$12.84 M(+2.7%) | -$45.93 M(+8.6%) |
| Dec 2019 | -$42.30 M(+18.5%) | -$12.50 M(+25.3%) | -$42.30 M(+8.0%) |
| Sep 2019 | - | -$9.97 M(-6.1%) | -$39.18 M(-0.7%) |
| Jun 2019 | - | -$10.62 M(+15.3%) | -$39.45 M(+7.0%) |
| Mar 2019 | - | -$9.21 M(-1.7%) | -$36.87 M(+3.3%) |
| Dec 2018 | -$35.71 M(+27.8%) | -$9.38 M(-8.4%) | -$35.71 M(+35.6%) |
| Sep 2018 | - | -$10.24 M(+27.2%) | -$26.33 M(+63.6%) |
| Jun 2018 | - | -$8.05 M(-0.1%) | -$16.10 M(+99.9%) |
| Mar 2018 | - | -$8.05 M | -$8.05 M |
| Dec 2017 | -$27.95 M | - | - |
FAQ
- What is RAPT Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for RAPT Therapeutics?
- What is RAPT Therapeutics annual EBITDA year-on-year change?
- What is RAPT Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for RAPT Therapeutics?
- What is RAPT Therapeutics quarterly EBITDA year-on-year change?
- What is RAPT Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for RAPT Therapeutics?
- What is RAPT Therapeutics TTM EBITDA year-on-year change?
What is RAPT Therapeutics annual EBITDA?
The current annual EBITDA of RAPT is -$125.85 M
What is the all time high annual EBITDA for RAPT Therapeutics?
RAPT Therapeutics all-time high annual EBITDA is -$27.95 M
What is RAPT Therapeutics annual EBITDA year-on-year change?
Over the past year, RAPT annual EBITDA has changed by -$41.10 M (-48.49%)
What is RAPT Therapeutics quarterly EBITDA?
The current quarterly EBITDA of RAPT is -$19.49 M
What is the all time high quarterly EBITDA for RAPT Therapeutics?
RAPT Therapeutics all-time high quarterly EBITDA is -$8.05 M
What is RAPT Therapeutics quarterly EBITDA year-on-year change?
Over the past year, RAPT quarterly EBITDA has changed by +$14.10 M (+41.98%)
What is RAPT Therapeutics TTM EBITDA?
The current TTM EBITDA of RAPT is -$113.61 M
What is the all time high TTM EBITDA for RAPT Therapeutics?
RAPT Therapeutics all-time high TTM EBITDA is -$8.05 M
What is RAPT Therapeutics TTM EBITDA year-on-year change?
Over the past year, RAPT TTM EBITDA has changed by +$3.52 M (+3.00%)